Abstract: Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.

Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.

Abstract: A data processing system is configured to perform a computer implemented method for facilitation of efficient processing of electronic messages via a network from message sources. The method includes receiving an electronic message including actionable object data and textual object data from a message source device. The actionable object data includes parameters actionable by at least one data processing transaction device to perform data processing transactions external to the network device and the textual object data including descriptors of the parameters actionable by the at least one data processing transaction device. The textual object data is operable by devices incompatible with the actionable object data. The method includes calculating an execution command for the data processing transaction in response to the actionable object data and based on at least the parameters of the actionable object data.

Abstract: Provided herein are compounds of Formulae (I) and (II), or pharmaceutically acceptable salts of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formulae (I) and/or (II), or a pharmaceutically acceptable salt of any of the foregoing.

Abstract: Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof.

Abstract: Methods, apparatus, systems and articles of manufacture to perform dot product calculations using sparse vectors are disclosed. An example dot product calculator includes a first logic AND gate to perform a first logic AND operation with a first input vector and a second input vector, the first logic AND gate to output a control vector; a second logic AND gate to perform a second logic AND operation with a difference vector and an inverse of the control vector, the second logic AND gate to output a mask vector; a third logic AND gate to output a first vector; a first counter to generate a first ones count based on a first total number of ones of the first vector; a fourth logic AND gate to output a second vector; a second counter to generate a second ones count; and a multiplier to generate a product.

Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

Abstract: Disclosed herein are aza-pyridone compounds, pharmaceutical compositions that include one or more aza-pyridone compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an orthomyxovirus infection, with an aza-pyridone compounds. Examples of an orthomyxovirus viral infection include an influenza infection.

Abstract: Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.

Abstract: Embodiments of the present invention provide a system and method to perform drying and testing of organometallic and organosilane precursor source ampoules that have been cleaned for re-use. The drying and quality control testing is performed in a single location with a single apparatus requiring only one manual connection/disconnection step of the ampoule to the apparatus. The testing includes analyses for residual moisture, entrained particulate matter, differential pressure, and helium leak checking.

Abstract: A high power electron tube, such as a magnetron, has the disadvantage that, to reduce the chances of the ceramic RF window failing in use, the manufacturing step entails a prolonged ageing period of powering the magnetron at low power on test, in order to drive any absorbed gases out of the RF window. According to the invention, the RF window 6 is internally glazed (8), which makes it possible to avoid the ageing period.

Abstract: Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.

Abstract: Methods, apparatus, systems and articles of manufacture to perform dot product calculations using sparse vectors are disclosed. An example dot product calculator includes a first logic AND gate to perform a first logic AND operation with a first input vector and a second input vector, the first logic AND gate to output a control vector; a second logic AND gate to perform a second logic AND operation with a difference vector and an inverse of the control vector, the second logic AND gate to output a mask vector; a third logic AND gate to output a first vector; a first counter to generate a first ones count based on a first total number of ones of the first vector; a fourth logic AND gate to output a second vector; a second counter to generate a second ones count; and a multiplier to generate a product.

Abstract: The disclosure includes antisense oligonucleotides, including gapmer antisense oligonucleotides, along with methods of making and use, e.g., against HBV.

Abstract: Provided herein are compounds of Formulae (I) and (II), or pharmaceutically acceptable salts of the foregoing, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formulae (I) and/or (II), or a pharmaceutically acceptable salt of any of the foregoing.

Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

Abstract: Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.

Abstract: Methods, apparatus, systems and articles of manufacture to perform dot product calculations using sparse vectors are disclosed. An example dot product calculator includes a counter to determine a trailing binary count of a control vector, the control vector corresponding to a first result of a first logic AND operation on a first bitmap of a first sparse vector and a second bitmap of a second sparse vector. The example dot product calculator further includes a mask generator to generate a mask vector based on the trailing binary count. The example dot product calculator further includes an interface to access a first value of the first sparse vector based on a second result of a second logic AND operation on the first bitmap and the mask vector and access a second value of the second sparse vector based on a third result of a third logic AND operation on the second bitmap and the mask vector.

Abstract: Methods, apparatus, systems and articles of manufacture to store and access multi-dimensional data are disclosed. An example apparatus includes a memory; a memory allocator to allocate part of the memory for storage of a multi-dimensional data object; and a storage element organizer to: separate the multi-dimensional data into storage elements; store the storage elements in the memory, the stored storage elements being selectively executable; store starting memory address locations for the storage elements in an array in the memory, the array to facilitate selectable access of data of the stored elements; store a pointer for the array into the memory.